New Findings on Nicotine Addiction and Treatment

  • Jed E. Rose
Part of the Nebraska Symposium on Motivation book series (NSM, volume 55)


Over the last 10 years, we have witnessed a rapid expansion in both the scientific understanding of tobacco addiction and in the range of pharmacotherapies available for smoking cessation treatment. These recent developments will be reviewed below, emphasizing the link between basic research and the development of new treatments. This link is bidirectional: increased knowledge gained from basic animal and human laboratory research informs the development of new treatments; in addition, however, findings from treatment studies help us test and refine hypotheses about underlying mechanisms. We will consider three main areas of treatment research: (1) pre-cessation administration of therapeutic agents, including nicotine, varenicline, mecamylamine and bupropion; (2) development of nicotine vaccines; and (3) progress towards tailoring cessation treatments based on a smoker’s genetic make-up.

Pre-cessation Administration of Pharmacologic Agents

Pre-cessation use of Nicotine...


Nicotine Replacement Therapy Nicotinic Receptor Rewarding Effect Nicotine Patch Smoking Cessation Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by an unrestricted grant on adult smoking cessation provided by Philip Morris USA, Inc. The author appreciates helpful suggestions on an earlier draft of this manuscript from Frederique Behm and Alexey Mukhin, M.D., Ph.D.


  1. Bouton, M. E., & Swartzentruber D. (1991). Sources of relapse after extinction in pavlovian and instrumental learning. Clinical Psychology Review, 11, 123–140.CrossRefGoogle Scholar
  2. Brewer, B. G., Roberts, A. M., & Rowell, P. P. (2004). Short-term distribution of nicotine in the rat lung. Drug and Alcohol Dependence, 75, 193–198.PubMedCrossRefGoogle Scholar
  3. Cardenas, L., Busto, U. E., MacDonald, A., & Corrigall, W. A. (2002). Nicotine patches and the subjective effects of cigarette smoking: A pilot study. Canadian Journal of Clinical Pharmacology, 9, 175–182.PubMedGoogle Scholar
  4. Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., et al. (2005). Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. Journal of Medicinal Chemistry, 48, 3474–3477.PubMedCrossRefGoogle Scholar
  5. Damaj, M. I., Carroll, F. I., Eaton, J. B., Navarro, H. A., Blough, B. E., Mirza, S., et al. (2004). Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Molecular Pharmacology, 66, 675–682.PubMedCrossRefGoogle Scholar
  6. Donny, E. C., Houtsmuller, E., & Stitzer, M. L. (2007). Smoking in the absence of nicotine: Behavioral, subjective and physiological effects over 11 days. Addiction, 102, 324–334.PubMedCrossRefGoogle Scholar
  7. Glover, E. D., Laflin, M. T., Schuh, K. J., Schuh, L. M., Nides, M., Christen, A. G., et al. (2007). A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction, 102, 795–802.PubMedCrossRefGoogle Scholar
  8. Hatsukami, D. K., Rennard, S., Jorenby, D., Fiore, M., Koopmeiners, J., de Vos, A., et al. (2005). Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clinical Pharmacology & Therapeutics, 78, 456–467.CrossRefGoogle Scholar
  9. Heading, C. E. (2007). Drug evaluation: Cyt-002-nicqb, a therapeutic vaccine for the treatment of nicotine addiction. Current Opinion in Investigational Drugs, 8, 71–77.PubMedGoogle Scholar
  10. Henningfield, J. E., & Jasinski, D. R. (1988). Pharmacologic basis for nicotine replacement. In O. F. Pomerleau & C. S. Pomerleau (Eds.), Nicotine replacement: A critical evaluation (pp. 35–61). New York: Alan R. Liss, Inc.Google Scholar
  11. Herrera, N., Franco, R., Herrera, L., Partidas, A., Rolando, R., & Fagerstrom, K. O. (1995). Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest, 108, 447–451.PubMedCrossRefGoogle Scholar
  12. Ishida, M., & Papini, M. R. (2007). Massed trial overtraining effects on extinction and reversal performance in turtles (geoclemys reevesii). The Quarterly Journal of Experimental Psychology Section B, 50, 1–16.CrossRefGoogle Scholar
  13. Lam, S., & Patel, P. N. (2007). Varenicline: A selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Cardiology in Review, 15, 154–161.PubMedCrossRefGoogle Scholar
  14. Lerman, C., Jepson, C., Wileyto, E. P., Epstein, L. H., Rukstalis, M., Patterson, F., et al. (2006). Role of functional genetic variation in the dopamine d2 receptor (drd2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials. Neuropsychopharmacology, 31, 231–242.PubMedGoogle Scholar
  15. LeSage, M. G., Keyler, D. E., Hieda, Y., Collins, G., Burroughs, D., Le, C., et al. (2006). Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl), 184, 409–416.CrossRefGoogle Scholar
  16. Levin, E. D., Westman, E. C., Stein, R. M., Carnahan, E., Sanchez, M., Herman, S., et al. (1994). Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms and attenuates rewarding effects of smoking. Journal of Clinical Psychopharmacolog, 14, 41–49.Google Scholar
  17. Martinez-Raga, J., Keaney, F., Sutherland, G., Perez-Galvez, B., & Strang, J. (2003). Treatment of nicotine dependence with bupropion sr: Review of its efficacy, safety and pharmacological profile. Addiction Biology, 8, 13–21.PubMedCrossRefGoogle Scholar
  18. Mays, K. L., Levin, M. E., Bak, K. M., Palmatier, M. I., Liu, X., Caggiula, A. R.,et al. (2007). Nicotine and bupropion have similar effects on responding for reinforcing non-drug stimuli. Presented at the 13th annual meeting of the Society for Research on Nicotine and Tobacco, February 21–24, Austin, Texas.Google Scholar
  19. Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006). Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Molecular Pharmacology, 70, 801–805.PubMedCrossRefGoogle Scholar
  20. Oncken, C., Gonzales, D., Nides, M., Rennard, S., Watsky, E., Billing, C. B., et al. (2006). Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine, 166, 1571–1577.PubMedCrossRefGoogle Scholar
  21. Orona, E., Foster, K., Lambert, R. W., & Gabriel, M. (1982). Cingulate cortical and anterior thalamic neuronal correlates of the overtraining reversal effect in rabbits. Behavioural Brain Research, 4, 133–154.PubMedCrossRefGoogle Scholar
  22. Palmatier, M. I., Matteson, G. L., Black, J. J., Liu, X., Caggiula, A. R., Craven, L., et al. (2007). The reinforcement enhancing effects of nicotine depend on the incentive value of non-drug reinforcers and increase with repeated drug injections. Drug and Alcohol Dependence, 89, 52–59.PubMedCrossRefGoogle Scholar
  23. Peters, M. J., & Morgan, L. C. (2002). The pharmacotherapy of smoking cessation. Medical Journal of Australia, 176, 486–490.PubMedGoogle Scholar
  24. Rose, J. E. (2006). Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl), 184, 274–285.CrossRefGoogle Scholar
  25. Rose, J. E., & Behm, F. M. (2004). Extinguishing the rewarding value of smoke cues: Pharmacological and behavioral treatments. Nicotine & Tobacco Research, 6, 523–532.CrossRefGoogle Scholar
  26. Rose, J. E., & Levin, E. D. (1991). Inter-relationships between conditioned and primary reinforcement in the maintenance of cigarette smoking. British Journal of Addiction, 86, 605–609.PubMedCrossRefGoogle Scholar
  27. Rose, J. E., Westman, E. C., Behm, F. M., Johnson, M. P., & Goldberg, J. S. (1999). Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan. Pharmacology, Biochemistry and Behavior, 62, 165–172.CrossRefGoogle Scholar
  28. Rose, J. E., Behm, F. M., Westman, E. C., & Kukovich, P. (2006). Pre-cessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine & Tobacco Research, 8, 89–101.CrossRefGoogle Scholar
  29. Rose, J. E., Lokitz, S. J., Garg, S., Turkington, T. G., Minton, R. C., Smith, H. C., et al. (2006). Highly dependent cigarette smokers show slower brain uptake of nicotine than less dependent smokers. Presented at the 35th annual meeting of the Society for Neuroscience, Atlanta, Georgia, October 14–18, 2006.Google Scholar
  30. Rose, J. E., Herskovic, J. E., Behm, F. M., & Westman, E. C. (2007). Pre-cessation treatment with nicotine patch. Significantly increases abstinence rates relative to conventional treatment. Presented at the 13th annual meeting of the Society for Research on Nicotine and Tobacco, February 21–24, Austin, Texas.Google Scholar
  31. Russell, M. A. H., & Feyerabend, C. (1978). Cigarette smoking: A dependence on high-nicotine boli. Drug Metabolism Reviews, 8, 29–57.PubMedCrossRefGoogle Scholar
  32. Schuurmans, M. M., Diacon, A. H., van Biljon, X., & Bolliger, C. T. (2004). Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: A randomized controlled trial. Addiction, 99, 634–640.PubMedCrossRefGoogle Scholar
  33. Shiffman, S., Ferguson, S. G., & Gwaltney, C. J. (2006). Immediate hedonic response to smoking lapses: Relationship to smoking relapse, and effects of nicotine replacement therapy. Psychopharmacology (Berl), 184, 608–618.CrossRefGoogle Scholar
  34. Shiffman, S., Scharf, D. M., Shadel, W. G., Gwaltney, C. J., Dang, Q., Paton, S. M., et al. (2006). Analyzing milestones in smoking cessation: Illustration in a nicotine patch trial in adult smokers. Journal of Consulting and Clinical Psychology, 74, 276–285.PubMedCrossRefGoogle Scholar
  35. Uhl, G. R., Liu, Q.-R., Drgon, T., Johnson, C., Walther, D., & Rose, J. E. (2007). Molecular genetics of nicotine dependence and abstinence: Whole genome association using 520,000 SNPs. BMC Genetics, 8, 1–11.CrossRefGoogle Scholar
  36. Valles, R., Rocha, A., & Nation, J. R. (2006). The effects of acquisition training schedule on extinction and reinstatement of cocaine self-administration in male rats. Experimental and Clinical Psychopharmacology, 14, 245–253.PubMedCrossRefGoogle Scholar
  37. Xian, H., Scherrer, J. F., Madden, P. A., Lyons, M. J., Tsuang, M., True, W. R., et al. (2003). The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine & Tobacco Research, 5, 245–254.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Center for Nicotine and Smoking Cessation ResearchDuke University Medical CenterDurhamUSA

Personalised recommendations